Trial Profile
Yttrium Y90Ibritumomab Tiutexan (Zevalin)as a consolidation treatment for patients with high grade non-Hodgkin's lymphoma aged >60 years.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2014
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- 29 Jul 2011 New trial record